Valeur202020212022202320242025Total du passif1.74 B1.73 B1.77 B1.89 B1.33 B1.51 BTotal des capitaux propres4.11 B4.27 B4.6 B4.95 B5.66 B6.09 BTotal du passif et des capitaux propres5.85 B6 B6.38 B6.84 B6.99 B7.59 BDette totale1.08 B1.08 B1.09 B1.09 B595.48 M597.29 MDette nette12.62 M67.47 M-206.23 M13.3 M-542.23 M-963.32 M
BioMarin Pharmaceutical Inc. - Common Stock
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.